Twist, Aster team up to launch AsterExome panel for cancer research
kentoh/iStock via Getty Images
- Twist Bioscience (NASDAQ:TWST) and Aster Insights are launching a next generation oncology panel AsterExome for cancer research.
- The company said the panel can simultaneously enable whole exome sequencing (WES) with additional coverage for target regions known to contain 620 genes associated with cancer.
- The AsterExome panel will be integrated into Aster's AVATAR program, which can enable informatics-based analysis of paired tumor and germline DNA and RNA sequencing data from patients consented via the Total Cancer Care (TCC) protocol.
- "We were able to blend targets from Aster Insights with Twist’s Exome 2.0 design to create a custom panel with high accuracy, efficiently designed to enable cancer research," said Twist Co-Founder and CEO Emily Leproust.